Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.